Single-fraction radiation therapy in patients with metastatic Merkel cell carcinoma

Cancer Medicine

Volumn 4, Issue 8, 2015, Pages 1161-1170

  Iyer, Jayasri G ^a   Parvathaneni, Upendra ^b   Gooley, Ted ^c   Miller, Natalie J ^a   Markowitz, Elan ^c   Blom, Astrid ^a   Lewis, Christopher W ^a   Doumani, Ryan F ^a   Parvathaneni, Kaushik ^a   Anderson, Austin ^a   Bestick, Amy ^a   Liao, Jay ^b   Kane, Gabrielle ^b   Bhatia, Shailender ^a,c,d   Paulson, Kelly ^a   Nghiem, Paul ^a,c,d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c USA   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

Author keywords

Merkel cell carcinoma; Merkel cell polyomavirus; Single fraction radiation therapy; Skin cancer

Indexed keywords

TUMOR ANTIGEN; VIRUS ANTIGEN;

ADULT; AGED; ANTIGEN PRESENTATION; ARTICLE; BONE METASTASIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMORBIDITY; EXPLORATORY RESEARCH; FEMALE; FOLLOW UP; HUMAN; IMMUNE DEFICIENCY; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; MALE; MERKEL CELL TUMOR; METASTASIS POTENTIAL; PATIENT SAFETY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION INJURY; RETROSPECTIVE STUDY; SINGLE FRACTION RADIOTHERAPY; SKIN; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VERY ELDERLY; VISCERA; ADVERSE EFFECTS; BONE TUMOR; CARCINOMA, MERKEL CELL; DISEASE COURSE; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PROCEDURES; RADIOTHERAPY PLANNING SYSTEM; SECONDARY; TIME FACTOR;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, MERKEL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PALLIATIVE CARE; RADIOTHERAPY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 85006201865     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.458     Document Type: Article

References (24)

1. Lemos, B. D., B. E. Storer, J. G. Iyer, J. L. Phillips, C. K. Bichakjian, L. C. Fang, et al. 2010. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J. Am. Acad. Dermatol. 63:751-761.
2. Miller, N. J., S. Bhatia, U. Parvathaneni, J. G. Iyer, and P. Nghiem . 2013. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr. Treat. Options Oncol. 14:249-263.
3. Tai, P. T., E. Yu, E. Winquist, A. Hammond, L. Stitt, J. Tonita, et al. 2000. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J. Clin. Oncol. 18:2493-2499.
4. Heath, M., N. Jaimes, B. Lemos, A. Mostaghimi, L. C. Wang, P. F. Penas, et al. 2008. Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J. Am. Acad. Dermatol. 58:375-381.
5. Paulson, K. G., J. G. Iyer, A. Blom, E. M. Warton, M. Sokil, L. Yelistratova, et al. 2013. Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage. J. Invest. Dermatol. 133:642-646.
6. Paulson, K. G., J. G. Iyer, A. R. Tegeder, R. Thibodeau, J. Schelter, S. Koba, et al. 2011. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J. Clin. Oncol. 29:1539-1546.
7. Sihto, H., T. Bohling, H. Kavola, V. Koljonen, M. Salmi, S. Jalkanen, et al. 2012. Tumor infiltrating immune cells and outcome of Merkel cell carcinoma: a population-based study. Clin. Cancer Res. 18:2872-2881.
8. Lee, Y., S. L. Auh, Y. Wang, B. Burnette, Y. Wang, Y. Meng, et al. 2009. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114:589-595.
9. Chow, E., K. Harris, G. Fan, M. Tsao, and W. M. Sze . 2007. Palliative radiotherapy trials for bone metastases: a systematic review. J. Clin. Oncol. 25:1423-1436.
10. Foro Arnalot, P., A. V. Fontanals, J. C. Galceran, F. Lynd, X. S. Latiesas, N. R. de Dios, et al. 2008. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother. Oncol. 89:150-155.
11. Hoskin, P. J., P. Price, D. Easton, J. Regan, D. Austin, S. Palmer, et al. 1992. A prospective randomised trial of 4 Gy or 8 Gy single doses in the treatment of metastatic bone pain. Radiother. Oncol. 23:74-78.
12. Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, et al. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45:228-247.
13. Howell, D. D., J. L. James, W. F. Hartsell, M. Suntharalingam, M. Machtay, J. H. Suh, et al. 2013. Single-fraction radiotherapy versus multifraction radiotherapy for palliation of painful vertebral bone metastases-equivalent efficacy, less toxicity, more convenient: a subset analysis of Radiation Therapy Oncology Group trial 97-14. Cancer 119:888-896.
14. Jeremic, B., Y. Shibamoto, L. Acimovic, B. Milicic, S. Milisavljevic, N. Nikolic, et al. 1998. A randomized trial of three single-dose radiation therapy regimens in the treatment of metastatic bone pain. Int. J. Radiat. Oncol. Biol. Phys. 42:161-167.
15. Badzio, A., E. Senkus-Konefka, B. A. Jereczek-Fossa, K. Adamska, S. Fajndt, I. Tesmer-Laskowska, et al. 2003. 20 Gy in five fractions versus 8 Gy in one fraction in palliative radiotherapy of bone metastases. A multicenter randomized study. J. Oncol. 53:261-264.
16. Wu, J. S., R. Wong, M. Johnston, A. Bezjak, and T. Whelan . 2003. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of pa inful bone metastases. Int. J. Radiat. Oncol. Biol. Phys. 55:594-605.
17. Sihto, H., T. Bohling, H. Kavola, V. Koljonen, M. Salmi, and S. Jalkanen, et al. 2012. Tumor infiltrating immune cells and outcome of merkel cell carcinoma: a population-based study. Clini. Cancer Res. 18:2872-2881.
18. Kwilas, A. R., R. N. Donahue, M. B. Bernstein, and J. W. Hodge . 2012. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer. Front Oncol. 2:104.
19. Litterman, A. J., D. M. Zellmer, K. L. Grinnen, M. A. Hunt, A. Z. Dudek, A. M. Salazar, et al. 2013. Profound impairment of adaptive immune responses by alkylating chemotherapy. J. Immunol. 190:6259-6268.
20. Sewell, H. F., C. F. Halbert, R. A. Robins, A. Galvin, S. Chan, and R. W. Blamey . 1993. Chemotherapy-induced differential changes in lymphocyte subsets and natural-killer-cell function in patients with advanced breast cancer. Int. J. Cancer 55:735-738.
21. Steele, T. A. 2002. Chemotherapy-induced immunosuppression and reconstitution of immune function. Leuk. Res. 26:411-414.
22. Kang, D. H., M. T. Weaver, N. J. Park, B. Smith, T. McArdle, and J. Carpenter . 2009. Significant impairment in immune recovery after cancer treatment. Nurs. Res. 58:105-114.
23. Hamid, O., C. Robert, A. Daud, F. S. Hodi, W. J. Hwu, R. Kefford, et al. 2013. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl. J. Med. 369:134-144.
24. Dewan, M. Z., A. E. Galloway, N. Kawashima, J. K. Dewyngaert, J. S. Babb, S. C. Formenti, et al. 2009. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res. 15:5379-5388.